Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. The company is headquartered in Bethesda, Maryland.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-10.59M |
| EBITDA | $-19.67M |
| Operating Margin | 0.00% |
| Return on Equity | -214.70% |
| Return on Assets | -81.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.33 |
| Price-to-Book | 5.82 |
| Price-to-Sales (TTM) | 255.50 |
| EV/Revenue | 138.33 |
| EV/EBITDA | -1.55 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $42.65M |
| Float | $41.65M |
| % Insiders | 2.29% |
| % Institutions | 19.24% |
Volatility is currently expanding
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26
BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in a virtual fireside chat and one-on-one meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held in a hybrid format from June 15-16, 2026.
MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph continues, with a difference of 4.8 points in the sum of MDS-UPDRS Part II and Part III scores between the two groups at Day 150 Most common benefits reported by study participants include meaningful improvements in specific functional areas such as smell and taste, sleep, and balance or gait BETHESDA, Md., May 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of an oral presentation at the 3rd International GBA1 Meeting 2026, held May 22-23, 2026, in Phoenix, AZ.
BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.
BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the 3rd International GBA1 Meeting 2026, being held May 22-23, 2026, in Phoenix, AZ.
BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update.
